The epithelial-mesenchymal transition (EMT) enhances cellular invasiveness and confers tumor cells with cancer stem cell-like characteristics, through transcriptional and translational mechanisms. The mechanisms maintaining transcriptional and translational repression of EMT and cellular invasion are poorly understood. Herein, the cell fate determination factor Dachshund (DACH1), suppressed EMT via repression of cytoplasmic translational induction of Snail by inactivating the Y box-binding protein (YB-1). In the nucleus, DACH1 antagonized YB-1-mediated oncogenic transcriptional modules governing cell invasion. DACH1 blocked YB-1-induced mammary tumor growth and EMT in mice. In basal-like breast cancer, the reduced expression of DACH1 and increased YB-1 correlated with poor metastasis-free survival. The loss of DACH1 suppression of both cytoplasmic translational and nuclear transcriptional events governing EMT and tumor invasion may contribute to poor prognosis in basal-like forms of breast cancer, a relatively aggressive disease subtype. Cancer Res; 74(3); 829-39. Ó2013 AACR.
Introduction
Dedifferentiation through activation of the embryonic epithelial-mesenchymal transition (EMT) program strongly enhances cancer cell motility and dissemination. EMT, a characteristic of embryonic development, wound healing, and tissue remodeling, involves a molecular program inducing abundance of transducer proteins (SNAIL, TWIST, and ZEB2), which coordinate the reduction in epithelial (E-cadherin) and induction of mesenchymal (N-cadherin, fibronectin, and vimentin) marker proteins (1, 2) . A variety of extracellular signals induce EMT, including TGF-b, and extracellular matrix components such as collagen and hyaluronic acid. Together, these pathways converge on EMT-inducing transcription factors, including SNAIL, Slug, ZEB1/2, Twist, FoxC2, ID1, and Goosecoid. EMT induction of tumor cells introduces cancer stem cell (CSC)-like properties with consequent therapeutic resistance and tumor recurrence. Induction of the EMT program involves both transcriptional and translational activities, although the mechanisms coordinating these activities are not well understood.
Y box-binding protein 1 (YB-1) is an oncogenic factor associated with the induction of EMT. In normal murine and human tissues YB-1 resides in the cytoplasm found in complexes with translationally inactive mRNA. The cap-independent translational activation of Snail and other developmentally regulated transcription factors occurs via a cytoplasmic pool of YB-1 (3) (4) (5) (6) . PI3K-AKT activation induces nuclear translocation of YB-1, wherein growth-promoting function occurs via binding to target sequences within genes governing tumorigenesis. Diverse target genes, including the EGFR, Her2, and c-Myc contain regulatory regions bound by YB-1. In transgenic mice, YB-1 is sufficient for the induction of mammary tumors characterized by a high degree of chromosomal instability (7) . YB-1 up regulates the transcription of cyclin A (8) , topoisomerase IIa (9) , and a variety of proteins involved in promoting migration and cellular invasion. YB-1 is overexpressed in hormone-dependent cancers arising in the breast, ovary, and prostate, and is not amplified. Rather induction of YB-1 expression likely occurs due to activation of the YB-1 promotor by transcription induction and/or loss of transcriptional repression (10) .
The Drosophila homolog of Dachshund (DACH1), the Dac gene, is a key member of the retinal determination gene network that specifies organismal development. The dachshund (dac), eya1, eyes-absent (eya), twin of eyeless (toy), teashirt (tsh), and sinocules (so) are expressed in progenitor cells, contributing to development of the eye and genitalia. Loss of DACH1 expression contributes to the expansion of neural progenitors, muscle satellite cell differentiation, and breast CSCs (11) (12) (13) . In recent studies, Dachshund repressed breast CSC expansion (11) . DACH1 expression is reduced in a variety of human cancers, including prostate and breast cancer (14, 15) . To understand at a high level of resolution the molecular mechanisms by which the cell fate determination factor DACH1 coordinates breast cancer cellular invasiveness and tumor initiating cell (TIC) properties, we sought to identify DACH1 interactive proteins that may participate in these distinct functions. Through proteomic analysis we identified YB-1 as a DACH1-binding protein. DACH1 repressed the translational induction of EMT by inactivating the cytoplasmic YB-1-mediated induction of Snail translation and in the nucleus DACH1 repressed a transcriptional program promoting cellular invasion. DACH1 suppresses mammary tumor EMT and invasion through the coordination of cytoplasmic translational and nuclear transcriptional activities.
Materials and Methods
Cell culture, plasmid construction, reporter genes, expression vectors, DNA transfection, luciferase assays, and proteomic analysis Cell culture, DNA transfection, and luciferase assays using the Snail 3 0 untranslated region (UTR) luciferase reporter gene, were performed as previously described (3) (4) (5) (6) . Proteomic analysis of DACH1 associated proteins was conducted as recently described (16) .
RNA isolation, RT-PCR, and quantitative real-time PCR
Total RNA was isolated from MDA-MB-231 cells infected with the DACH1 expression vector system, using TRIzol (17) .
Microarray and cluster analysis
DNA-free total RNA isolated from MDA-MB-231 cells expressing green fluorescent protein (GFP) or DACH1 were used to probe Affymetrix Gene 1.0 arrays (Affymetrix). RNA quality was determined by gel electrophoresis. Probe synthesis and hybridization were performed as previously described (18) .
Immunohistochemistry and immunofluorescence
Immunohistochemical analysis of human breast cancer was conducted using a polyclonal DACH1 antibody (19) , polyclonal KLF4 antibody (SC-20691), and monoclonal antibody to YB-1 (Cell Signaling Technology, 4202S). Human breast cancer tissue arrays were from Biomax.
Western blot analysis and immunoprecipitation study
Whole cells were analyzed in RIPA buffer (150 mol/L NaCl, 20 mmol/L Tris-HCI, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L Na 3 VO 3 , 2.5 mmol/L sodium pyrophosphate, 1 mmol/L b-glycerophosphate, 1% Triton Â100), supplied with proteinase inhibitors. Protein was separated by a 9% SDS-PAGE. Antibodies used in Western blot analysis were from Santa Cruz Biotech and included cyclin A (sc-596), cyclin B1 (sc-595), cdc25A (sc-97), YB-1 (sc-101198), HAepitope (sc-7392), c-Myc (sc-40), EZRIN (sc-20773), cyclin D1 (sc-20044), and b-actin (sc-47778). Antibodies from Cell Signaling Technology were YB-1 (D299), ZO-1 (5406p), SNAIL (3879p), N-cadherin (4061p), ZEB1 (3396p), and SLUG (9585p). Immunoprecipitation-Western blot analysis study was performed as described previously (19) .
Mammosphere formation
Mammosphere formation assays were conducted as previously described (20) . ALDEFLOUR staining and immunostaining of cell surface markers by fluorescence-activated cell sorting analysis for breast CSCs, was based on prior publications (21, 22) .
Migration and invasion analysis
Transwell migration assays were performed as described previously (23) .
Tumor implantation study
A total of 2 Â 10 5 MDA-MB-231 cells expressing GFP control or DACH1 or shYB-1 were implanted subcutaneously into 5-to 6-week-old ethymic female nude mice purchased from National Cancer Institute (Frederick, MD). The tumor growth was measured weekly for 4 to 5 weeks using a digital caliper. Tumor weight was measured when mice were sacrificed.
Results

DACH1 binds YB-1 in breast cancer cell lines
DACH1 has been implicated in the regulation of stem cells of several tissue types, including muscle, neural, and breast (12, 13, 11) . We conducted a proteomic analysis to identify candidate DACH1-binding partners that may govern this function. DACH1 protein complexes were prepared from HEK293T cells transfected with the FLAG-DACH1 expression vector and DACH1-associated proteins were resolved on a 6% and 10% hydrochloride gel and silver stained ( Supplementary Fig. S1A ). Analysis of the proteins recovered from the gel through in-gel trypsin digestion and in sequential ms/ms identified a $50 kDa protein identical to YB-1 ( Supplementary Fig. S1B ). HEK293T cells expressing FLAG-tagged DACH1 and Myc-tagged YB-1, demonstrated the association of YB-1 with DACH1 in immunoprecipitation-Western blotting ( Supplementary Fig. S1C ). MDA-MB-231 cells were used to examine the binding of endogenous YB-1 to DACH1. The MDA-MB-231 cells were stably transduced with an expression vector encoding DACH1 and immunoprecipitation, conducted with a FLAG antibody directed to the amino-terminus of DACH1, coprecipitated endogenous YB-1 ( Supplementary Fig. S1D ).
The carboxyl domain of YB-1 binds to the carboxyl terminus of DACH1
The YB-1 protein consists of three key domains; a C-terminal domain (CTD), which contributes to DNA/RNA binding (24), a highly conserved cold shock domain (CSD), which forms an antiparallel b barrel to facilitate binding to nucleic acids as a chaperone protein, and a nonconserved variable N-terminal domain characterized by four alternating clusters of basic and acidic amino acids, which is both alanine and proline rich and is thought to be involved in transactivation (25) . Nuclear cytoplasmic shuffling of YB-1 is controlled by both a distinct nuclear localization signal and cytoplasmic retention signals in the CTD (26) . HEK293T cells were transfected with a series of FLAG-tagged YB-1 mutant expression vectors and HA-tagged DACH1 (Fig. 1A) . The FLAG-IP precipitated YB-1 fragment. Western blotting for DACH1 using the HA antibody demonstrated the association of DACH1 with each YB-1 fragment but a failure to bind the CSD alone (Fig. 1B) . Immunoprecipitation of DACH1 with the HA antibody demonstrated DACH1 binding to the YB-1 C-terminus (Fig. 1C) . In GST pulldown 6-His DACH1 bound GST-expressed YB-1. The DACH1 DBD (DNA-binding domain) did not bind YB-1 (Fig. 1D) . Thus, the C-terminus of YB-1 was sufficient for binding DACH1 and the YB-1 CSD domain was incapable of binding DACH1 (Fig. 1A and B).
DACH1 exists in three isoforms (DACH1a, b, and c) and each of the DACH1 isoforms were capable of binding YB-1 with similar affinity (Fig. 1E and F) . DACH1 mutant expression vectors were coexpressed with YB-1 wild-type (WT) to define the domains of DACH1 governing association with YB-1 (Fig.  1G) . Deletion of the DDBD of DACH1 did not affect binding to YB-1; however, deletion of the C-terminus (DACH1 DC) abolished YB-1 binding and the C-terminus was sufficient for YB-1 binding (Fig. 1H ).
Phosphorylation determines DACH1 nuclearcytoplasmic translocation
To determine whether DACH1 is phosphorylated, cellular extracts from HEK293T cells were examined before and after Flag-tag DACH1 3×Flag tag
Flag-tag YB-1
His-DACH1 YB-1 Fig. S2B ). The electrophoretic mobility of the DACH1 protein expressing a mutation of S439 was similar to the CIP treated cells expressing DACH1 wt ( Supplementary Fig. S2C ). By immunohistochemistry (IHC), the DACH1 protein was located primarily in the nucleus ( Supplementary Fig. S2D ). The S439A S441 and S529 mutants were cytoplasmic. These findings suggest DACH1 phosphorylation determines the cytoplasmic versus nuclear location.
DACH1 inhibits and YB-1 induces breast cancer cellular EMT in cell lines
As YB-1 located in the cytoplasmic pool regulates translational control to induce EMT and DACH1 expression reduced cytoplasmic YB-1, we examined the possibility that DACH1 expression may reduce YB-1-dependent EMT. The MBA-MB-231 breast cancer cell line stably transduced with a ponasterone-inducible DACH1 expression vector demonstrated the expression of FLAG-tagged DACH1 upon the addition of ponasterone A, which reduced the abundance of Ezrin, SNAIL, and ZEB-1 ( Fig. 2A) . Vinculin and GDI, two loading controls for protein abundance were unchanged. Consistent with a role for YB-1 to induce EMT, short hairpin RNA (shRNA) to YB-1, reduced the abundance of SNAIL and ZEB-1 ( Fig. 2A) . Immunohistochemical staining demonstrated a reduction in ZEB-1 upon expression of DACH1 (Fig. 2B) . The abundance of SNAIL was reduced by either DACH1 expression (Fig. 2C ) or shRNA to YB-1 (Fig. 2C) . The reduction in SNAIL abundance by YB-1 shRNA in MDA-MB-231 cells is consistent with prior findings in MCF10A-Ras breast cancer cells (6) . Together, these studies suggest that DACH1 inhibits YB-1-induced EMT.
DACH1 antagonizes YB-1-mediated gene expression
To examine further the mechanisms by which DACH1 antagonized YB-1-mediated EMT, we considered the possibility that DACH1 may antagonize the transcriptional function of YB-1. To determine the gene expression pathway regulated by either DACH1 expression or YB-1 shRNA reflecting endogenous YB-1, MDA-MB-231 cells transduced with either a ponasterone-inducible DACH1 cDNA, or shRNA to YB-1, were subjected to microarray gene expression analysis (Fig. 3) . The relative mRNA abundance of DACH1 and YB-1 was determined in the cell lines after treatment with ponasterone A for 24 hours (Fig. 3A) . DACH1 mRNA was induced 6-fold. YB-1 mRNA levels were not affected by expression of DACH1. YB-1 shRNA reduced YB-1 abundance by 75% without affecting DACH1 levels.
We next examined the functional pathways and the gene expression modules governed by DACH1 and YB-1 by interrogating the mRNA derived from MDA-MB-231 cells expressing inducible DACH1, either with or without YB-1 shRNA (Fig.  3B-D) . DACH1 expression repressed gene expression associated with "tumor cell movement" and "cell proliferation" but not "EMT" (Fig. 3B-D) . shRNA to YB-1 or expression of DACH1 had similar effects on the expression of genes in the tumor cell proliferation and tumor migration and invasion pathways. KLF4 was a member of each DAVID (Database for Annotation, Visualization, and Integrated Discovery, david.abcc.ncifcrf. gov) functional pathway that was repressed by DACH1 and shRNA to YB-1. Functional analysis was conducted in vivo using MDA-MB-231 cells expressing a ponasterone A-inducible DACH1 and/or YB-1 shRNA. Cells were introduced into immunodeficient mice. DACH1 expression inhibited cell proliferation and tumor growth, as did YB-1 shRNA (Fig. 3E and F) . DACH1 expression or YB-1 shRNA identified KLF4 as a common gene target associated with inhibition of tumor cell migration and tumor cell proliferation. Quantitation of KLF4 mRNA in multiplicate experiments demonstrated that DACH1 expression reduced KLF4 levels by >50% as did shRNA to YB-1 (Fig. 3G) . Immunohistochemical staining of the ponasteroneinducible DACH1 MDA-MB-231 cells transduced with shRNA to YB-1 demonstrated that DACH1 or YB-1 shRNA reduced KLF4 abundance (Fig. 3H ). These studies demonstrate there is substantial overlap in GEO-terms and gene expression regulated by either DACH1 expression or YB-1 shRNA.
YB-1 induction of breast cancer invasiveness is antagonized by DACH1
Ectopic expression of YB-1 confers invasiveness of MCF10A cells (6) . Transmigration and cellular invasion may involve distinguishable or common processes. To determine whether endogenous YB-1 promotes cellular migration in MDA-MB-231 cells, shRNA to YB-1 was used to transduce cells. To determine whether DACH1 could antagonize YB-1 induction of invasion, three-dimensional (3D) Matrigel invasion assays were conducted. The expression of DACH1 was sufficient to inhibit MDA-MB-231 cell Transwell migration (Fig. 4A ), Matrigel invasion (Fig. 4B ) and collagen invasion (Fig. 4C and D) . shRNA to YB-1 similarly reduced migration and invasion (Fig. 4A-C) .
The induction of EMT may enrich gene expression associated with embryonic stem cells (ES) and/or TIC. To determine whether YB-1 abundance may induce TIC, we deployed a widely accepted model of mammosphere formation in which the number of mammospheres reflects symmetrical division in multipotential cells. MDA-MB-231 cells were stably transduced with ponasterone-inducible DACH1 and/or shRNA to YB-1. Increased DACH1 expression or reduced YB-1 abundance via shRNA reduced the number of mammospheres by >60% in multiple generations (Fig. 4D) . shRNA to YB-1 reduced mammosphere size by $15% (Fig. 4E) . 
DACH1 expression regulates nuclear cytoplasmic distribution of YB-1 and thereby YB-1-mediated capindependent translation of Snail
The finding that DACH1 repression of YB-1 shRNA induced EMT, without affecting expression of genes governing EMT, led us to consider alternate mechanisms. Cytoplasmic YB-1 is known to activate cap-independent translation of mRNA encoding Snail and other factors implicated in activators of mesenchymal genes (6) . As cytoplasmic, not nuclear YB-1, governs EMT, we considered the possibility that DACH1 expression may regulate the relative abundance of cytoplasmic versus nuclear pools of YB-1. To examine the effects of DACH1 expression, on YB-1 subcellular localization, IHC for DACH1 and YB-1 was conducted on postasterone-inducible DACH1 expressing breast cancer cell lines. Expression of DACH1 in SUM159 cells was readily detectable upon ponasterone A treatment in a nuclear compartment, detected by the FLAG antibody to the N-terminal tag of DACH1. YB-1 was predominately cytoplasmic in location. Upon expression of DACH1, YB-1 became predominantly nuclear (Fig. 5A) . Similar findings were made in MDA-MB-231 cells in which expression of DACH1 was associated with increased nuclear abundance of YB-1, detected either by IHC (Fig. 5B) or by Western blot analysis of nuclear versus cytoplasmic fractions (Fig. 5C ). As the DACH1 phosphorylation sites determined nuclear localization, we assessed whether DACH1 induction of YB-1 nuclear translocation involved the DACH1 phosphorylation sites (Supplementary Fig. S3A ). DACH1 WT was located in the nucleus, identified by a-FLAG IHC (Supplementary Fig. S3A ). The DACH1 phosphorylation mutant was predominantly cytoplasmic. YB-1, detected by the myc epitope was cytoplasmic, and cotransfection with DACH1 WT induced nuclear translocation of YB-1. In contrast, cotransfection with the DACH1 phosphorylation mutant (DACH1 S439, 441, and 529A) resulted in predominantly cytoplasmic YB-1 immunostaining (Supplementary Fig. S3A ). Several pathways have been shown to influence YB-1 location, including the PI3K-AKT pathway (27) , which phosphorylated YB-1 at Ser102. To determine whether DACH1-mediated YB1 nuclear translocation involved AKT, we deployed an expression vector encoding a point mutation of YB-1 (Ser102; Supplementary Fig. S3B ). Cotransfection of DACH1 induced nuclear translocation of YB-1 or YB-1 (Ser102) to a similar level (Supplementary Fig. S3B ). These findings suggest DACH1-mediated YB-1 nuclear translocation does not involve the AKT pathway.
We had shown that DACH1 expression or YB-1 shRNA reduced SNAIL abundance. The role of SNAIL1 as an inducer of EMT is well established. The Snail1 mRNA harbors specific motifs in its 5 0 UTR that are conserved and are responsible for cap-independent translation by YB-1. YB-1 has been shown to induce cap-independent translation of genes enhancing EMT (6), including Snail in MCF10AT cells. (The MCF10AT subclone is derived by transformation of the immortalized benign MCF10A human mammary epithelial cells with oncogenic Ha-Ras and subsequent passaging through mouse xenotransplants). We examined the role of DACH1 in YB-1-dependent regulation of Snail. We deployed a Snail1 5 0 UTR linked to the luciferase reporter gene. Conditions of starvation, or starvation combined with rapamycin, restrict cap-dependent translation. Consistent with previous observations that YB-1 induces cap-dependent translation of Snail1 5 0 UTR-Luc activity (6), we also show that YB-1 induced Snail 5 0 UTR-Luc activity. Ectopic expression of DACH1 repressed YB-1 activation (Fig. 5D) . The induction of Snail 5 0 UTR-Luc activity by YB-1 requires the cytoplasmic pool. DACH1 expression reduces the cytoplasmic YB-1. The phosphorylation point mutants of DACH1 are localized to the cytoplasm and fail to undergo nuclear translocation. Consistent with a model in which DACH1 inhibits YB-1 cytoplasmic EMT function through inducing nuclear translocation, each of the DACH1 phosphorylation point mutants failed to repress YB-1-mediated induction of Snail 5 0 UTR-Luc activity; indeed the mutants conveyed a dominant positive effect on Snail1 5 0 UTR-Luc activity (Fig. 5E ).
YB-1 and DACH1 expression is inversely correlated in luminal A and basal human breast cancer
We examined further the relationship between YB-1 and DACH1 expression in breast cancer cell line and tissues. We examined the relative mRNA levels for DACH1 in luminal (n ¼ 15) and basal (n ¼ 14) breast cancer cell lines. DACH1 relative mRNA levels were reduced and YB-1 levels increased in basal breast cancer cell lines compared with luminal breast cancer cell lines (Fig. 6A) . Previous studies had demonstrated reduced DACH1 abundance in human breast cancer correlating with poor prognosis (19) . RNA expression of DACH1 was higher in luminal cancer with decreased abundance in human basal cancer. In contrast, YB-1 levels were increased in human basal breast cancer compared with luminal cancer (Fig. 6A) . Immunohistochemical staining was conducted on normal human breast tissue, with comparison made with human breast cancer (Fig. 6B) . DACH1 was expressed in normal human tissue with reduced expression in basal breast cancer. YB-1 expression was reduced in normal breast tissue but increased in basal breast cancer (Fig. 6C) .
To determine the relative abundance of DACH1 and YB-1 in human breast cancer, we examined gene expression of 2,550 breast cancer samples (Fig. 6D) . The tumors were subclassified by the genetic subtypes of luminal A, luminal B, basal, normallike, and HER2 (Fig. 6D) . Molecular subtyping allowed us to identify an enhancement of DACH1 expression with low YB-1 expressing tumors as luminal A (Fig. 6E) and conversely increased YB-1 expression with low DACH1 levels was identified in the basal phenotype (Fig. 6G) . In the other genetic subtypes, there was no specific statistically significant association between YB-1 and DACH1 expression. These studies raised the possibilities that DACH1 may regulate the expression of YB-1 in a subset of breast cancers.
To determine whether a reduction of DACH1 abundance in the basal breast cancer subtype correlated independently with clinical outcome, we examined a series of basal, claudinpositive, breast cancer samples and determined the correlation with metastasis-free, relapse-free, and overall survival. A reduction of DACH1 abundance was associated with reduced survival probability, relapse-free, and metastasis-free survival ( Supplementary Fig. S4A-S4C ). Similar analysis demonstrated that increased levels of YB-1 were associated with reduced metastasis-free survival, relapse-free survival, and overall survival ( Supplementary Fig. S4D-S4F ). proteins to conduct its diverse functions. DACH1-associated proteins include members of the Retinal Determination Gene Network (Six; Eya), the coactivators CBP/p300, c-Jun, and CA150.
YB-1 induces EMT at least in part through directly activating cap-independent translation of messenger RNAs encoding SNAIL, Twist, and ZEB2/Sip1 and other activators of EMT (6) . Herein, DACH1 inhibited YB-1-mediated induction of capindependent translation of Snail 5 0 UTR-Luc activity. The cytoplasmic pool of YB-1 enhances the translation of EMT genes, including SNAIL. DACH1 expression induced the translocation of YB-1 from the cytoplasmic to a nuclear pool. Previous studies have identified mechanism governing YB-1 cytoplasmic-nuclear translocation, including AKT and MAPK (27) . In this study, point mutation of the AKT phosphorylation sites of YB-1(Ser102) did not affect DACH1-mediated nuclear translocation of YB-1, suggesting the mechanism is AKT-independent. The role of other factors showed to regulate YB-1 nuclear translocation, including DNP63a (28) remain to be determined. These studies are the first to define the importance of specific DACH1 phosphorylation sites in regulating function, as DACH1 S439, S441, and S529 were required for nuclear translocation and repression of the Snail 5 0 UTR-Luc reporter. Together, these studies are consistent with a model in which DACH1 promotes nuclear translocation of YB-1, thereby reducing the cytoplasmic translation inducing pool of YB-1.
DACH1 expression, or YB-1 shRNA, inhibited breast cancer cellular Transwell migration, invasion and 3D Matrigel invasion. Analysis of the transcriptional modules regulated by DACH1 expression or YB-1 shRNA identified KLF4 mRNA abundance as a common target of YB-1 and DACH1 governing cell proliferation and migration. Kruppel-like factor 4 (KLF4) is highly expressed in approximately 70% of breast cancers functioning as an oncogene and serving as a distal target of stem or progenitor cell expansion in MDA-MB-231 and MCF7 cells (29, 11) . It will be of interest to determine whether KLF4 serves as a common functional distal target in both DACH1-and YB1 shRNA-mediated transcriptional repression of tumor cell migration and growth in vivo.
Herein, DACH1 inhibited YB-1-mediated induction of the breast CSC phenotype. Mammosphere number, which serves as a useful surrogate marker of breast CSCs, was maintained by endogenous YB-1 and repressed by DACH1. YB-1 upregulates markers of stem cells, including p63, CD44, and CD10 and seems to link the acquisition of the mesenchymal phenotype and the stem cell associated gene expression. DACH1 regulates gene transcription both directly and indirectly. DACH1 binds a forkhead-like consensus sequence and ChIP-Seq analysis identified DACH1-bound ES cell inducing target genes (Sox2, Nanong, and EKLF). In addition, DACH1 binds to several transcription factors (c-jun, Six; ref. 30) , and thereby regulates gene expression through indirect mechanisms. The current findings are consistent with recent studies demonstrating the importance of endogenous DACH1 in reprogramming mammary breast CSCs via transcriptional induction (11) and herein through indirect mechanisms via binding of YB-1. It will be of interest to determine whether genetic deletion of DACH1 is capable of affecting murine mammary gland stem cells in vivo and thereby mammary gland development.
Extending the previous studies showing reduced expression of DACH1 in human breast cancer (19) and the ability of DACH1 to block breast cancer metastasis (23) , herein, DACH1 and YB-1 abundance were inversely correlated in luminal A and basal breast cancer. Although prior analysis established YB-1 upregulation correlated with tumor aggressiveness and loss of DACH1 expression across all breast cancer types demonstrated a modest but significant increase in cumulative months of survival (n ¼ 2,125 patients), the precise mechanisms remained largely unknown. Analysis of $2,250 human breast cancer samples demonstrated the features of EMT gene expression in a subset of basal-like human breast cancers. These studies are the first to identify genetic subtypes in which reduced DACH1 expression and increased YB-1 expression correlate and show a significant adverse outcome for DACH1 loss or YB-1 overexpression in the basal claudin-positive subtype. The clinical outcome of this subset of patients reinforces the critical functional significance of the balance between YB-1 and DACH1 in governing the EMT switch and proliferative/invasive features of tumors. The loss of DACH1 and increased YB-1 levels may contribute to the EMT phenotype of basal-like breast cancer.
This study may have broad implications for understanding the process of EMT, and tumor stem cell expansion in other tumor types. The abundance of YB-1 is increased in a variety of malignancies, including breast, prostate, liver, lung, and brain, and experimental data suggest an oncogenic role for YB-1 in tissue culture and mouse models (31) . Conversely, DACH1 abundance is reduced in these same malignancies, with a growing body of evidence to suggest DACH1 may function as a new type of tumor suppressor (14, (32) (33) (34) 15 ). It will be of interest to determine in future studies whether the interaction between DACH1 and YB-1 plays a broad role in other malignancies.
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